Company ProfilePremium

Cosmecca Korea Co., Ltd.

Company Profile Analysis

Ticker: 241710.KQ주식회사 코스메카코리아

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cosmecca Korea Co., Ltd. - Company showcase

Year Founded & Workforce

1999

531 Employees

Cosmecca Korea Co., Ltd. logo

Cosmecca Korea Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cosmecca Korea Co., Ltd. Overview

Cosmecca Korea is the third-largest pure-play cosmetics ODM/OEM in Korea, behind Cosmax and Kolmar Korea. It brands its model as "OGM" (Original Global-standard Manufacturing). It formulates, develops, and manufactures skincare, functional/OTC, and colour cosmetics for third-party brands. It does not sell under its own consumer brands. Production runs through three entities:

  • The Korean parent, with plants in Eumseong and Cheongju and a new Ochang site under construction.

  • Majority-owned Englewood Lab, with plants in Totowa (New Jersey) and Incheon.

  • A small China subsidiary in Pinghu.

The investment case rests on the global boom in Korean indie and "K-derma" brands, whose exports flow through Korean ODMs. From FY2023 to FY2025, consolidated revenue rose from KRW 470.7 bn to KRW 640.9 bn and operating margin from 10.4% to 13.0%. 1H 2026 revenue grew 46.8%. The company has a medium-term revenue target of KRW 1 trillion and a ~KRW 200 bn capacity build-out at Ochang. Its US manufacturing base gives it a hedge against tariffs.


What the company does

Cosmecca Korea is a business-to-business cosmetics manufacturer. Its services cover:

  • formulation research and development,

  • product proposal and concept development (ODM),

  • contract manufacturing to customer specification (OEM),

  • quality assurance and regulatory support,

  • packaging procurement under "turnkey" contracts.

It serves brand owners: Korean indie brands, global prestige and mass beauty houses, and US indie and OTC brands.

S&P's company description, carried on StockHub, lists its products as:

  • skincare (lotions/toners, creams, essences, cleansers, mask sheets, scalp, body and bath products),

  • functional products (whitening, anti-wrinkle, UV protection, acne care),

  • colour cosmetics (BB/CC creams, foundation, lipstick, mascara).

Company self-description

The company now calls itself a "global cosmetics OGM (Original Global-standard Manufacturing) specialist." Management uses the term to stress:

  • production to international regulatory standards (Korea MFDS, US FDA OTC monograph, Health Canada, Australia TGA, halal),

  • a Korea–US two-hub structure,

  • proprietary formulation development.

The company credits its growth to the following (Cosmorning and CosinKorea, 2025–2026):

  • order wins from Korean and global indie brands,

  • new-format development (it claims it launched the world's first triple-function BB cream),

  • tailored proposals and fast response,

  • automation, including the "Cosmecca Production System (CPS)".

Independent characterisation

Economically, Cosmecca is a capacity-constrained, working-capital-intensive contract manufacturer whose volumes track its clients' sell-through. Key features:

Revenue model: almost entirely product revenue (per-unit manufacturing). Small service income exists (Englewood Lab reports ~3% "services," Q2 2026). There is no subscription or licensing revenue.

Turnkey vs. non-turnkey mix: this materially changes reported revenue but not necessarily margin. Under turnkey contracts Cosmecca buys the containers and passes their cost through in the price. Under non-turnkey ("용기 사급") contracts the client supplies packaging. A large Englewood Lab Korea client switched to non-turnkey in 2024, which depressed reported revenue (Yuanta, Jan 2025; Hana, Jul 2025).

Value-chain position: midstream. Upstream are raw-material and packaging suppliers; supply disruptions hit 2Q26 China results and the 3Q26 Korean results (KB, Oct 2026). Downstream are brand owners and, beyond them, retailers and marketplaces such as Amazon, TikTok Shop, Olive Young, Ulta and Sephora.

Customer types: - Korean indie/derma brands that export globally (the main growth driver since 2023).

  • Global multinationals (Estée Lauder was cited as a key US/EU client as early as FY2016; Hankyung, Feb 2017).

  • US indie and OTC sunscreen brands (Englewood Lab: >93% of revenue from US customers at end-2024; Dealsite, Aug 2025).

  • Chinese local and global brands (China subsidiary).

End-markets: prestige and masstige skincare, dermocosmetics, sun care/OTC, base and colour make-up (cushions, BB), masks (hydrogel), and expanding into hair and body care.

Customer concentration

The company does not name its clients. Broker commentary tracks them by letter:

  • At 4Q25, client "D" grew 35% QoQ and became the largest customer (KB, Feb 2026).

  • In 2Q26, client "A" entered the top ten, and customers ranked 5th–10th grew from ~1% to 2–3% of revenue each (Hana, Aug 2026).

  • At Englewood Lab Korea, orders from customer "G" weakened in 2Q26, cutting that unit's profit 13% YoY (Hana, Aug 2026).

These data show concentration is falling but still material.

Strategy

Stated strategic themes (paraphrased from company statements)

  1. KRW 1 trillion revenue. The chairman set a medium-to-long-term goal of KRW 1 trn consolidated revenue in his 2025 New Year address. The company describes it as medium-term (Dealsite, Jul 2026). Hana's FY2027 estimate is KRW 1,024 bn.

  2. "Global top-tier OGM." Become a top-tier global ODM through R&D investment, formulation diversification, and new orders from K-beauty and global indie brands (Chairman Cho, Nov 2025).

  3. Korea–US dual production hub. Build "Made in USA" capacity and integrate Korea–US technology collaboration and product development. Unify ERP across the two entities to improve cost structure and link production and sales networks (company, Mar 2026).

  4. Category expansion. Move from a skincare core into hydrogel masks, sun care, and premium hair and body (Ochang), and into OTC sunscreen (Englewood).

  5. Customer diversification. Reduce dependence on top clients by deepening SKUs with existing clients and adding new indie brands.

  6. Governance and capital-market upgrade. Build an audit committee, chair separation, and compliance programme, with a possible renewed KOSPI transfer. Management said no decision has been made.

  7. 2026 management keyword. A four-character motto, "비천도해" (飛天渡海; roughly "fly through the sky and cross the sea"), announced at the 2 January 2026 kickoff.

Initiatives in the last 24 months

InitiativeDateScope / targetStatus
Englewood Lab tender offer IFeb 202539%→50%; ~KRW 21.9 bnCompleted
Englewood Lab tender offer IIMar 202650%→66.7%; ~KRW 43.1 bnCompleted (25 Mar 2026)
Cheongju hydrogel-mask plantApr 2025>1m sheets/month initiallyOperating
Englewood RTG OTC sunscreen platform1Q–2Q 2025FDA-compliant ready-to-go sunscreensLaunched; driving US growth
Englewood automation (Totowa, Incheon)2024–2025Productivity and marginEffects visible (EWLK OPM 34% in 4Q25)
Sales reorganisationEarly 2025Domestic and global marketing merged into Global Sales DivisionDone
China turnaround2025–2026New GM; halal; Shanghai R&D; target breakeven in 2026 (Yuanta, Feb 2026)Still loss-making in 2Q26
Pangyo Central Research Institute4Q 2025New R&D hubOpened
KOSPI transfer attemptMay–Sep 2025Transfer listingFailed KRX preliminary review
Governance overhaulMar 2026Audit committee, chair separation, 6 committees, e-votingDone
Ochang plant acquisitionJun 2026KRW 64 bn land and buildingsAgreed; Hansol says closing within 2026
Ochang facility build-outSep 2026KRW 136 bn; first phase 2027; staged to 2030Announced
SP Beauty Global mergerDec 2026 (planned)Simplify US packaging ownershipPending
Government "AI application product rapid commercialisation support programme"2026 (exact date not confirmed)Selected participantReported (Asia Economy headline, Jul 2026)
ESG/packagingUndatedMOU with Green Bio on biodegradable containersReported (Sellernow)

Guidance

Guidance itemOriginal (Feb 2026)Revised (May 2026)Revised (Aug 2026)
FY2026 consolidated revenue growth (%)152030
FY2026 operating margin (%)13.013.5Not captured in sources reviewed

A 30% increase implies FY2026 revenue of ≈KRW 833 bn.

No formal medium-term margin or ROE targets were identified beyond the KRW 1 trn revenue ambition.

Products & Services

Cosmecca discloses no SKU-level pricing. Pricing is contract-based per unit, and turnkey contracts include packaging pass-through.

Korea (parent)

Product line / capabilityDescription and capabilitiesTarget customerStatus / yearFlagship / evidence
Basic skincare (기초)Toners, lotions, creams, essences/serums, ampoules; the core of the Korean book and the main margin driverKorean indie and derma brands; global brandsCore since foundingHana (Aug 2026): high-margin skincare focus drives Korean OPM to 13.7% in 2Q26
K-derma / dermocosmeticsSkin-science formulations (barrier, calming, actives)K-derma brands going globalGrowth category 2025–26Company (CosinKorea, Aug 2026) cites rising global demand for K-derma; Kyobo highlights it
CleansersCleansing oils, foams, balmsIndie brandsOngoingCompany says its in-house-developed cleansing oil was an Amazon bestseller (Kukinews, Nov 2025)
Peel / exfoliating shotsConcentrated exfoliating serum format ("필샷", peel shot)Indie brands2025 hitCompany says it reached TikTok best-seller status (Kukinews, Nov 2025)
Base make-up (BB/CC, cushion, foundation)Multi-function bases; cushion compactsGlobal and Korean brandsSince 2000sCompany claims the world's first triple-function BB cream; Yuanta (Jan 2025) cites bulk cushion orders
Colour cosmeticsLipsticks, mascara, other colour itemsBrand ownersOngoingS&P description
Functional cosmeticsWhitening, anti-wrinkle, UV, acne-care functional claims (MFDS)Brand ownersOngoingS&P description
Sheet and hydrogel masksHydrogel masks from the Cheongju plant (>1m sheets/month at start; medium-term revenue ambition reported by Meritz)Indie brands, globalCheongju plant opened Apr 2025Meritz (May 2025)
Scalp, body and bath careScalp care, body lotions and washesBrand ownersExpandingOchang plant to add premium hair and body (company, Jun 2026)
Sun careSunscreens (MFDS functional)Global indie brandsExpanding via OchangCompany (Jun 2026)
ODM development servicesFormulation development, proposals, stability and efficacy testing, regulatory dossiersAll customersOngoingPangyo Central Research Institute
Turnkey supplyPackaging procurement and assemblyCustomers preferring a one-stop serviceOngoingIR books split revenue into turnkey and non-turnkey

Englewood Lab (US & Korea)

Product line / capabilityDescriptionTarget customerStatusFlagship / evidence
Skincare (US-made)"Made in USA" skincare at the Totowa, NJ cGMP plantUS indie brands, prestige brands, K-beauty brands seeking US productionCore93%+ of 2024 revenue from US customers (Dealsite)
OTC sunscreens — "RTG OTC"Ready-To-Go FDA OTC-compliant sunscreen bases that brands can launch quicklyK-beauty and US indie brands entering US sun careDevelopment completed 1Q25; selling from 2Q25Cosmorning (May 2025); OTC SKU expansion drove 3Q25 (Hanwha)
Other OTC drug-cosmeticsAcne and other monograph OTCs; in-house OTC Testing LabUS brandsOngoingEnglewood IR (OTC Testing Lab)
Colour cosmeticsLimited colour rangeUS brands~7% of revenueEnglewood disclosure
EWLK Incheon productionHigh-margin production for a key global client (EWLK OPM ~31–34% in 2025)Global brand client "G"OngoingYuanta (Aug 2025, Feb 2026)
CertificationscGMP, Health Canada, Australian TGAExport customersHeldEnglewood IR books

Revenue mix, 2Q26 (Englewood Lab disclosure via Butler.works): basic skincare 67%, functional/OTC 23%, colour 7%, services 3%, other 1%.

China (Cosmecca China)

Product lineDescriptionTargetStatusEvidence
Colour cosmeticsColour-led portfolioChinese local and global brandsOngoingCosmorning (Aug 2025) headline on colour-led turnaround
Prestige skincareNew prestige skincare launchesChinese brands4Q25KB (Feb 2026): China revenue +3.9% on prestige skincare
Sun-care and whitening functionalsKorea–China joint-lab productsChina and Southeast AsiaIn development 2025–26Kukinews (Nov 2025)
Halal-certified productsHalal certification for China and Southeast AsiaSoutheast Asian marketsIn progressCosmorning (Nov 2025)

Packaging (SP BEAUTY GLOBAL Inc.)

A US packaging entity held through SP Beauty Global. Product and revenue details are not publicly disclosed. It is to be held directly by the parent after the December 2026 merger.

Financial Narrative

Source for all tables: S&P Global Market Intelligence via StockAnalysis.com (K-IFRS consolidated). Ratios were computed by the analyst as noted.

Per-share data and margins

Dividend notes:

  • FY2025 DPS of KRW 370 is per S&P.

  • FY2024 DPS of KRW 100 is implied by S&P's reported +270% dividend growth and by the 0.18% yield on brokers' June 2025 pages. Brokers showed a 0% yield before FY2024.

CAGR FY2021–FY2025: revenue 12.7%; operating income 42.8%; EPS 50.3%.

TTM to Jun 2026 (S&P): revenue KRW 772.05 bn; operating income KRW 99.63 bn (12.9%); EBITDA KRW 117.36 bn; net income to parent KRW 63.82 bn; EPS KRW 5,976.

1H 2026 (company, Dealsite): revenue KRW 411.2 bn (+46.8%); operating profit KRW 53.9 bn (+52.7%); net income KRW 39.9 bn (+99.5%).

Commentary — income statement:

FY2021–FY2022 trough: Revenue was flat at ~KRW 400 bn and operating margin fell to 2.6% in FY2022. Causes:

  • China losses (combined net losses of KRW 2.1 bn in 2021 and 5.1 bn in 2022; Dealsite),

  • under-utilised capacity built in 2018–19,

  • weak domestic road-shop clients.

FY2023 inflection: Gross margin jumped 650 bp to 22.6% as Korean indie-brand exports surged and Englewood Lab grew 36.5%. Operating leverage on a largely fixed cost base produced a 374% rise in operating profit.

FY2024 consolidation: The Korean parent carried the group (+22.3% revenue, +94% OP). Englewood Lab revenue fell 12% (customer turnkey switch and inventory adjustment) and China kept shrinking. Net income was flattered by a KRW 9.2 bn FX gain.

FY2025 acceleration: Revenue grew 22.2%, with Korea up ~34% and Englewood up 19%. Gross margin reached 24.6%. SG&A rose 33% (incentives, quality provisions, the Pangyo R&D centre). The effective tax rate normalised to 25.7%, which capped net-income growth at 6%.

1H 2026: Strongest period on record. Korean parent revenue was +91% in 1Q26 and +63% in 2Q26.

Balance sheet

At 30 June 2026 (S&P):

  • Total assets KRW 734.7 bn; cash and short-term investments KRW 91.0 bn.

  • Receivables KRW 209.8 bn; inventory KRW 109.0 bn.

  • Total debt KRW 233.0 bn, of which short-term borrowings KRW 159.7 bn and current long-term debt KRW 7.8 bn; net debt KRW 142.0 bn.

  • Common equity KRW 273.8 bn; minority interest KRW 60.8 bn.

  • BVPS KRW 25,639.

Additional paid-in capital fell from KRW 69.0 bn (FY2024) to KRW 47.1 bn (Jun 2026). This is consistent with the Englewood Lab tender premiums being booked as equity transactions with non-controlling interests (analyst interpretation).

Cash flow

TTM to Jun 2026 (S&P): OCF KRW 55.6 bn; capex KRW 49.6 bn; FCF KRW 6.0 bn; net borrowing KRW 57.4 bn; other financing −KRW 43.2 bn.

The −KRW 22.1 bn in FY2025 and −KRW 43.2 bn TTM match the 2025 (~KRW 21.9 bn) and 2026 (~KRW 43.1 bn) Englewood Lab tender offers.

Commentary — cash flow:

  • Cash conversion is weak relative to earnings. FY2025 OCF was 95% of net income incl. minorities, but FCF was negative because:

    • receivables rose by KRW 41.8 bn and inventory by KRW 14.4 bn,

    • capex reached KRW 61.4 bn (buildings jumped from KRW 79.5 bn to KRW 168.1 bn gross; Pangyo Central Research Institute and Cheongju plant).

  • In 1H 2026 receivables rose a further ~KRW 53 bn, and inventory rose ~KRW 30 bn on rapid growth.

  • The Englewood tender offers (~KRW 65 bn combined) and capex were funded by short-term borrowing. Short-term debt rose from KRW 78.3 bn at end-2024 to KRW 159.7 bn at June 2026.

  • The Ochang commitment (≈KRW 200 bn, of which KRW 64 bn is the land and buildings purchase) is roughly 3× FY2025 OCF. Further borrowing or other funding is likely; no equity issuance has been announced.

Ratios (analyst-computed from S&P data)

TTM June 2026 (S&P): ROE 24.8%; ROA 9.5%; ROIC 16.2%; current ratio 1.30; debt/equity 0.70; debt/EBITDA 1.99; interest coverage 18.3x; asset turnover 1.17; Altman Z 3.21; Piotroski F 5.

Commentary — ratios:

  • Returns have structurally reset, with ROIC rising from low single digits to mid-teens.

  • DSO has drifted up from 69 to 88 days. This reflects longer terms granted to indie-brand clients during rapid growth and is a credit-risk monitorable.

  • Leverage is moderate on EBITDA (net debt/EBITDA 0.9x at FY2025; ~1.2x TTM June 2026). However, the debt is heavily short-dated (~72% due within a year at June 2026), which creates refinancing exposure while the Ochang build is under way.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)FY2023FY2024FY2025

Korea (parent)

268.8328.7441.5

Englewood Lab (US+Korea, consolidated)

206.8182.2216.8

China (Cosmecca China)

50.640.434.0

Intersegment eliminations

-55.5-27.0-51.4

Consolidated revenue

470.7524.3640.9

Segment operating profit (KRW Bn)

Segment operating profit (KRW Bn)FY2023FY2024FY2025

Korea (parent)

22.944.547.7

Englewood Lab (consolidated)

28.918.837.4

China

—-1.1-1.9

Consolidated operating profit

49.260.483.5

Revenue by Segment (%) and Segment Margins & Growth (%)

Segment metric (%)FY2023FY2024FY2025

Korea OPM

8.513.510.8

Englewood Lab OPM

14.010.317.3

China OPM

—-2.7-5.6

Korea revenue YoY growth

—22.334.3

Englewood Lab revenue YoY growth

36.5-11.919.0

China revenue YoY growth

—-20.1-15.8

Korea share of gross segment revenue

51.159.663.8

Englewood Lab share of gross segment revenue

39.333.031.3

China share of gross segment revenue

9.67.34.9

Quarterly Metric Details

Quarterly metric (KRW Bn)1Q252Q253Q254Q251Q262Q26

Consolidated revenue

118.4161.7182.4178.1185.1226.1

Consolidated operating profit

12.323.027.220.921.932.1

Korea revenue

74.3110.0129.8127.3142.2178.8

Korea operating profit

8.013.814.511.317.824.5

Englewood Lab revenue

42.557.561.854.549.751.9

Englewood Lab operating profit

4.610.113.29.35.68.7

China revenue

8.88.68.18.5—7.7

China operating profit

-0.6-1.1-0.60.4—-1.2

Income Statement and Margin Analysis (%)

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Revenue

396.5399.4470.7524.3640.9

Revenue growth (%)

16.90.717.911.422.2

Cost of revenue

324.6335.0364.2400.2483.5

Gross profit

71.964.4106.6124.1157.4

SG&A

31.433.736.340.153.2

R&D expense

11.813.613.313.816.9

Operating income (EBIT)

20.110.449.260.483.5

D&A

16.416.716.817.816.5

EBITDA

36.527.165.978.2100.0

Interest expense

3.03.74.03.23.5

FX gain (loss)

2.9-0.10.09.2-0.3

Pre-tax income

17.56.446.167.677.9

Income tax

0.50.412.213.920.0

Net income incl. minorities

17.06.033.953.757.8

Minority interest

8.13.311.610.912.4

Net income to parent

8.92.722.342.845.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Per-Share Data and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

EPS basic (KRW)

8342492,0904,0084,255

EPS diluted (KRW)

8342492,0904,0084,255

Dividend per share (KRW)

000100370

Gross margin (%)

18.116.122.623.724.6

Operating margin (%)

5.12.610.411.513.0

EBITDA margin (%)

9.26.814.014.915.6

Net margin to parent (%)

2.20.74.78.27.1

Effective tax rate (%)

3.15.826.520.625.7

Balance Sheet and Per-Share Data

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Total assets

391.6392.8432.6518.0631.8

Cash and short-term investments

30.126.439.464.481.6

Accounts receivable

75.380.3108.8114.5155.3

Inventory

67.071.265.667.078.8

Property, plant and equipment

155.0155.0159.1207.2248.2

Goodwill and intangibles

42.440.237.836.335.6

Accounts payable

30.434.244.138.760.7

Short-term debt incl. current LTD and leases

77.183.679.890.7137.9

Long-term debt incl. leases

50.837.428.931.734.0

Total debt

127.9121.0108.7122.4172.0

Net debt

97.894.669.358.090.3

Common equity (parent)

142.3146.7169.5218.4252.7

Minority interest

54.160.472.689.283.5

Total equity

196.3207.0242.2307.6336.2

Working capital

47.943.866.684.982.3

Book value per share (KRW)

13,31913,73215,87420,45023,663

Cash Flow

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

7.916.742.069.555.0

Change in working capital

-22.4-11.3-22.2-2.7-28.8

Capital expenditure

9.011.618.648.761.4

Free cash flow

-1.15.123.420.8-6.3

Dividends paid (consolidated, incl. to NCI)

0.00.00.01.32.3

Share buybacks

0.00.00.00.00.0

Net debt issued (repaid)

-1.8-10.3-13.23.248.2

Other financing (NCI share purchases)

0.00.00.00.0-22.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE to parent, year-end equity (%)

6.31.813.219.618.0

ROA, NI incl. NCI / year-end assets (%)

4.31.57.810.49.1

ROIC, NOPAT at 22% tax / (equity + net debt) (%)

5.32.712.312.915.3

Current ratio (x)

1.351.311.431.501.33

Debt / equity (x)

0.650.580.450.400.51

Net debt / EBITDA (x)

2.683.491.050.740.90

Interest coverage, EBIT / interest (x)

6.82.812.218.923.6

Asset turnover, revenue / year-end assets (x)

1.011.021.091.011.01

Days sales outstanding

69.373.484.479.788.4

Days inventory outstanding

75.377.665.761.159.5

Days payables outstanding

34.237.344.235.345.8

Cash conversion cycle (days)

110.4113.7105.9105.5102.1

Revenue by Region

Region by producing entity (KRW Bn)FY2023FY2024FY2025

Korea (parent)

268.8328.7441.5

United States (Englewood Lab, incl. EWLK Incheon)

206.8182.2216.8

China

50.640.434.0

Regional growth (YoY %)

Regional growth (YoY %)FY2023FY2024FY2025

Korea (parent)

—22.334.3

United States (Englewood Lab)

36.5-11.919.0

China

—-20.1-15.8

Capital Markets

ItemValueSource

Latest close

KRW 111,800 (12 Oct 2026)

Money Today

52-week high / low

KRW 155,500 / 61,200

WiseReport

1-month return

−21.1% (to 2 Oct 2026)

WiseReport

3-month return

+30.5% (to 2 Oct 2026)

WiseReport

6-month return

+41.4% (to 2 Oct 2026)

WiseReport

1-year return

+52.4% (to 2 Oct 2026)

WiseReport

3-year return

≈+311% (KRW 27,200 on 15 Sep 2023 to KRW 111,800)

Hanwha (Sep 2023); analyst calculation

5-year return

The stock troughed near KRW 6,500 in 2022–23 (52-week low cited Sep 2023)

Hanwha

Beta (5Y)

1.07

S&P

Valuation Multiples

MultipleCosmecca Korea

Market cap (KRW Bn)

1,194

Enterprise value incl. NCI (KRW Bn)

1,397

P/E TTM (x)

18.7

P/E on Hana FY2026E (x)

15.5

EV/EBITDA TTM (x)

11.9

EV/Sales TTM (x)

1.81

P/B (x)

4.36

Dividend yield (%)

0.33

Analyst Ratings & Targets

BrokerDateRatingTarget price (KRW)

KB Securities

13 Oct 2026

Buy

140,000

Kyobo Securities

11 Aug 2026

Buy

150,000

NH Investment & Securities

Aug 2026

Buy

140,000

Hanwha Investment & Securities

Aug 2026

Buy

130,000

Samsung Securities

8 Jul 2026

Buy

110,000

Yuanta Securities

Jul 2026

Buy

120,000

S&P consensus (11 analysts)

Sep 2026

Strong Buy

127,727 average

Dividend history

Dividend historyFY2021FY2022FY2023FY2024FY2025

DPS (KRW)

000100370

Payout to parent NI (%)

0002.58.7

Debt bucket (KRW Bn)

Debt bucket (KRW Bn)Jun 2026

Short-term borrowings

159.7

Current portion of long-term debt

7.8

Current leases

2.6

Long-term debt

58.4

Long-term leases

4.6

Total debt

233.0

Analyst Conclusions

Guidance and consensus

Forecast (KRW Bn)FY2025AFY2026EFY2027E
Revenue (Hana)640.9832.51,024.3
Operating profit (Hana)83.5112.6145.3
Revenue (Hanwha, May 2026)640.9788.0869.0
Operating profit (Hanwha, May 2026)83.5106.0122.0

Management guidance: FY2026 revenue +30% YoY (≈KRW 833 bn), raised twice in 2026 from +15%. The revised margin guidance is not captured; the prior guide was 13.5%.

Broker forecasts: - KB quarterly path: 3Q26E revenue KRW 219.9 bn / OP KRW 31.0 bn; 4Q26E revenue KRW 220.5 bn / OP KRW 30.4 bn. This implies FY2026E revenue of ≈KRW 851.6 bn and OP of ≈KRW 115.4 bn.

S&P three-year forecasts: revenue +19.0% and EPS +28.9%.

Bull case

  1. Structural share gain in K-beauty ODM. Korean parent revenue grew 91% and 63% in 1Q and 2Q26, well above Korea's +27% export growth. Broadening clients (5th–10th clients now 2–3% each) suggest growth is not single-client driven.

  2. Operating leverage plus ownership step-up. OPM has expanded from 2.6% to ~13% in three years. Raising the Englewood stake to 66.7% adds attributable earnings; Hanwha's FY2026E controlling NI is KRW 73 bn (+61%).

  3. Capacity unlock and category expansion. Ochang from 2027 targets masks, sun care, and hair and body, making Hana's FY2027 KRW 1 trn revenue achievable at stable margins.

Bear case

  1. Cash conversion and leverage. FCF was negative in FY2025, and receivables plus inventory rose ~KRW 83 bn in 1H26. Short-term debt doubled to KRW 160 bn before the ~KRW 200 bn Ochang spend. A demand pause would expose the balance sheet.

  2. Cyclical, fad-driven demand. Indie hits have short lives. 3Q26 is already expected to miss on supply bottlenecks, and US destocking is recurring. The 21% 1-month share-price drop shows sentiment sensitivity.

  3. Governance overhang. Two family executives were indicted, the 2025 KOSPI transfer was rejected, and there is a 39% family bloc. These factors could cap the multiple and delay a KOSPI move.

Catalysts and monitorables (next 12 months)

  • 3Q26 results (~10 Nov 2026): size of the miss, and evidence of 4Q order recovery.

  • FY2026 results (~Feb 2027) and FY2027 guidance.

  • Ochang financing structure and the 2027 start-up timetable.

  • Progress of the sons' trial.

  • Englewood EWLK client order trends; RTG OTC traction.

  • China reaching breakeven.

  • Receivable days and short-term debt.

  • Any renewed KOSPI transfer filing.

  • Confirmation of the quarterly dividend policy.

  • KRW/USD.

Analyst verdict

Cosmecca Korea has moved from a sub-scale, low-margin contract manufacturer to the fastest-growing and most profitable of Korea's three listed cosmetics ODMs.

Earnings trajectory: Operating profit rose eightfold from the FY2022 trough of KRW 10.4 bn to KRW 83.5 bn in FY2025. TTM operating profit is near KRW 100 bn, and management raised FY2026 revenue guidance twice to +30%.

Quality of growth: It is driven by a broadening base of Korean indie and derma clients rather than one hero brand. Englewood Lab gives Cosmecca a rare US manufacturing platform as tariffs push brands toward local production.

Strategic progress: Raising its Englewood stake to two-thirds and committing ~KRW 200 bn to Ochang give credibility to the KRW 1 trillion revenue ambition. Hana's FY2027 forecast already reaches it.

The balance sheet and governance have not kept pace with the income statement:

Funding: Free cash flow is near zero because receivables, inventory, capex, and two tender offers have been funded with short-term bank debt, now KRW 160 bn.

Execution risk: The Ochang build roughly triples annual capex needs just as 3Q26 shows supply-chain strain and US client destocking.

Governance: The August 2026 indictment of the founder's two sons and the failed 2025 KOSPI transfer are reminders that governance remains a discount factor, despite the March 2026 board reforms.

At ~KRW 112,000 the shares trade on roughly 15–16x FY2026E earnings and ~12x TTM EV/EBITDA. That is a premium to the company's own history but modest relative to its growth and returns (TTM ROIC ~16%, ROE ~25%). The sell-side is uniformly positive, with targets of KRW 110,000–150,000.

Net assessment: fundamentally attractive and structurally advantaged, with growth quality validated by customer diversification. Execution on Ochang, working-capital discipline, and resolution of the governance overhang are the variables that will decide whether the market rewards Cosmecca with a peer-level or premium multiple. Investors should treat the 3Q26 print, the 4Q26 order recovery, and the Ochang funding plan as the key near-term tests.


APPENDIX — SOURCE REGISTER

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / role notesPrior roles / education / age

Cho Im-rae (조임래)

Chairman and Co-CEO; founder

Founded the company in 1999; CEO since founding

—

Park Eun-hee (박은희)

Co-CEO

Named co-CEO in 2025–2026 press and IR. Listed as lead holder of the largest shareholder group (39.0% with related parties)

—

Cho Hyun-seok (조현석)

President (사장), Cosmecca Korea

Heads the Global Sales Division and Management Support Division. Took global sales leadership in 2025 with a mandate to fix China. Holds ~3%

Founder's eldest son. Indicted Aug 2026

Cho Hyun-chul (조현철)

CEO, Englewood Lab

Leads US operations. Holds ~3% of Cosmecca

Founder's second son. Indicted Aug 2026

Kim Hyung-yeol (김형열)

General Manager, Cosmecca China

Hired Mar 2025

Formerly at Chinese cosmetics brand Proya

“—” = not publicly disclosed.

Board of Directors

NameRoleNotes

Choi Su-gyu (최수규)

Outside director; Board Chair; audit committee member

Chair separated from CEO by articles amendment, Mar 2026

Koo Bon-kwang (구본광)

Outside director; Audit Committee Chair

Former member of the KRX KOSPI listing and disclosure committee

Kim Ju-deok (김주덕)

Outside director; audit committee member

—

Two inside directors

Executive directors

Names not confirmed in sources reviewed; likely include the co-CEOs

Major Shareholders

HolderStake (%)Date / source

Park Eun-hee and related parties (4)

39.0

Hanwha, May 2026

National Pension Service (and 1 related)

12.5

Hanwha, May 2026 (up from 6.2% in Sep 2023)

KB Asset Management (and 1 related)

6.1

Hanwha, May 2026

Cho Hyun-seok

~3 (included in insider group)

Asia Economy, Sep 2026

Cho Hyun-chul

~3 (included in insider group)

Asia Economy, Sep 2026

Foreign investors (aggregate)

18.7

Hanwha, May 2026 (8.95% in Jan 2025)

Insiders (S&P definition)

45.0

StockAnalysis, Sep 2026

Institutions (S&P definition)

31.2

StockAnalysis, Sep 2026

Free float

~5.87m shares (55%)

StockAnalysis

Competitive Landscape

Key Competitors

CompetitorListingSegment overlapRevenue (latest)Positioning vs Cosmecca

Cosmax

KOSPI 192820

Korea, US, China skincare, colour, sun care ODM

FY2025 KRW 2,398.8 bn (+10.7%); OP KRW 195.8 bn

Self-described global #1 cosmetics ODM; ~3.7× Cosmecca's revenue; Korea unit KRW 1,526.4 bn

Kolmar Korea

KOSPI 161890

Korea and US skincare and sun care ODM; also pharma (HK inno.N)

FY2025 KRW 2,722.4 bn; OP KRW 239.6 bn (consolidated, incl. pharma)

Sun care leader; non-cosmetics ~half of revenue; US plants

C&C International

KOSDAQ 352480

Colour cosmetics (lip, base) ODM

—

Colour specialist; China presence

Hankook Cosmetics Manufacturing

KOSPI 003350

Korean contract manufacturing

—

Smaller domestic OEM

Intercos

Euronext Milan (ICOS)

Global colour, skincare ODM (Europe, US, Asia)

—

Global colour leader

KDC/One

Private

North American contract manufacturing

—

US competitor to Englewood Lab

Nihon Kolmar

Private (Japan)

Japanese ODM

—

Japan market

Toyo Beauty

Japan

Japanese ODM

—

Japan market

Cosmax USA / Cosmax West

Subsidiary

US ODM

Cosmax US revenue FY2025 KRW 132.6 bn

Direct US rival to Englewood

Kolmar USA

Subsidiary

US ODM (sun care)

2024 KRW 57.9 bn (+55%)

Direct US rival

In-house manufacturing at large brand houses (Amorepacific, LG H&H)

KOSPI

Captive production

Amorepacific FY2025 KRW 4.25 trn

Substitute rather than direct competitor

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricCosmecca KoreaCosmaxKolmar Korea

Revenue (KRW Bn)

640.92,398.82,722.4

Revenue growth (%)

22.210.7—

Operating profit (KRW Bn)

83.5195.8239.6

Operating margin (%)

13.08.28.8

R&D intensity (%)

2.6——

Company Snapshot

$451M

Revenue

531

Employees

1999

Founded

Eumseong-gun, South Korea

Headquarters

SWOT Analysis

Strengths

  • Margin leadership. FY2025 OPM 13.0% and EBITDA margin 15.6%, the highest among Korea's big-three ODMs (Cosmax 8.2%) (S&P; Cosmax disclosure).
  • Growth momentum. Revenue CAGR of 12.7% (FY2021–25) and 1H26 growth of +46.8%. Record quarterly revenue of KRW 226.1 bn in 2Q26.
  • US manufacturing footprint. Englewood Lab's Totowa plant (~211m units) serves a customer base that is 93%+ US; tariffs increase its value.
  • Customer diversification is improving. Customers ranked 5–10 rose from 1% to 2–3% of revenue each, and a new client entered the top 10 in 2Q26 (Hana).
  • Returns. ROIC rose from 2.7% (FY2022) to 15.3% (FY2025, analyst-computed); TTM ROE was 24.8% (S&P).
  • Regulatory breadth. cGMP, FDA OTC, Health Canada, TGA, and halal (in progress) support multi-market clients.

Weaknesses

  • Free cash flow. FY2025 FCF was −KRW 6.3 bn; TTM June 2026 FCF was KRW 6.0 bn against net income of KRW 63.8 bn.
  • Short-dated borrowing. ~KRW 167 bn of borrowings were due within 12 months at June 2026, out of KRW 233 bn total debt.
  • Rising receivables. DSO rose from 69 to 88 days (FY2021–25); receivables reached KRW 209.8 bn at June 2026.
  • China losses. China revenue fell to KRW 34.0 bn in FY2025 and posted a KRW 1.2 bn loss in 2Q26.
  • Earnings volatility at EWLK from a single key client (2Q26 EWLK profit −13% YoY).
  • Family control and governance gaps. The KRX rejected the KOSPI transfer in Sep 2025, with board independence among the reported concerns.

Opportunities

  • Ochang capacity (≈KRW 200 bn) unlocks hydrogel masks, sun care, and hair and body from 2027.
  • The KRW 1 trillion revenue target is credible: Hana's FY2027E revenue is KRW 1,024 bn.
  • Higher Englewood ownership (66.7%) raises the profit attributable to Cosmecca shareholders.
  • US OTC sunscreen and K-beauty brands needing US-made product.
  • KOSPI transfer after the governance overhaul could broaden the investor base.
  • New markets via halal (Southeast Asia, Middle East) and China functional products.

Threats

  • Indie-brand fad risk. Volumes depend on hit SKUs with short lifecycles.
  • Competitor capacity. Cosmax and Kolmar are both expanding capacity in 2026.
  • Supply-chain disruption. Packaging shortages cut 3Q26 growth (KB).
  • FX. The 3Q26 miss was partly attributed to unfavourable FX (KB).
  • Legal and reputational risk from the indictment of two family executives (Aug 2026).
  • US trade policy shifts that could reverse the reshoring advantage, or tariffs on Korean exports that hit Korea-made client products.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
6 Feb 2025Tender offer for 11% of Englewood Lab at KRW 10,000Raised stake to 50%; first step of US consolidation
21 Feb 2025FY2024 preliminary results: revenue KRW 524.3 bn, OP KRW 60.4 bnRecord year; Korea +22% offset US and China declines
Mar 2025China GM Kim Hyung-yeol (ex-Proya) hired; sales reorganisedChina turnaround push
Apr 2025Cheongju hydrogel-mask plant operationalNew category
12 May 20251Q25: revenue KRW 118.4 bn (−5.8%), OP KRW 12.3 bn (−10.5%)Trough quarter (Meritz: "1Q is the bottom")
May 2025RTG OTC sunscreen development completed at EnglewoodUS growth platform
May 2025KOSPI transfer listing application filedCapital-markets ambition
11 Aug 20252Q25: revenue KRW 161.7 bn (+12.5%), OP KRW 23.0 bn (+27.2%); 39% above consensus OPTurn to growth
Sep 2025KOSPI transfer fails KRX preliminary reviewGovernance gaps flagged
6 Nov 20253Q25: record revenue KRW 182.4 bn (+44%), OP KRW 27.2 bn (+78.8%), NI KRW 22.3 bn9M OP exceeded FY2024
7 Nov 2025Daishin raises TP to KRW 100,000; Kiwoom holds KRW 89,000Sell-side re-rating
4Q 2025Pangyo Central Research Institute relocation; ~KRW 5 bn one-offsR&D investment
2 Jan 2026Chairman sets 2026 keyword "비천도해"Growth ambition
2 Feb 2026Investor tour of the Central Research InstituteIR engagement
20 Feb 2026FY2025: revenue KRW 640.9 bn, OP KRW 83.5 bn; 4Q25 KRW 178.1 bn / KRW 20.9 bn (slight miss)FY2026 guidance +15% / 13% OPM
23 Feb 2026Yuanta TP KRW 96k→120k; KB TP to KRW 120kRe-rating
3 Mar 2026Tender offer to lift Englewood stake to 66.7% at KRW 13,000US control
Mar 2026AGM: audit committee, chair separation, e-votingGovernance
25 Mar 2026Englewood tender offer successfulStake ~66.7%
8 May 20261Q26: revenue KRW 185.1 bn (+56.4%), OP KRW 21.9 bn (+78%); Korea +91%Guidance raised to +20% / 13.5%
5 Jun 2026Ochang plant purchase (KRW 64 bn) from Hansol TechnicsCapacity
16 Jun 2026Hanwha: order backlog above 1Q level; FY2026E revenue KRW 793 bnMomentum
8 Jul 2026Samsung Securities TP KRW 90k→110kRe-rating
Jul 2026Dealsite series: KRW 1 trn goal; governance; leverageMedia scrutiny of leverage
10 Aug 20262Q26: record revenue KRW 226.1 bn (+39.8%), OP KRW 32.1 bn (+39.3%), NI KRW 20.3 bn; OP 16% above consensusGuidance raised to +30%
11 Aug 2026Shares up >16% intraday to a 52-week high; Kyobo TP KRW 150k, NH KRW 140kPeak sentiment
Aug 2026 (reported 7 Sep)Founder's sons indicted (no detention) for alleged insider trading in Englewood Lab shares in 2018Governance and legal overhang; not a mandatory disclosure per KRX
Early Sep 2026KRW 136 bn Ochang facility investment; total ~KRW 200 bnLargest capex commitment in company history
Sep 2026Merger of SP Beauty Global scheduled for Dec 2026Structural simplification
2 Oct 2026Shares close KRW 110,000 (−4.7% on the day; −21% over 1M)De-rating from August peak
13 Oct 2026KB TP KRW 120k→140k. 3Q26E revenue KRW 219.9 bn and OP KRW 31.0 bn, 2.3% / 4.3% below consensus, due to packaging supply bottlenecks, FX, and US client destocking. 4Q26E above consensusNear-term softness, structural upgrade

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 396.5 Bn in FY2021 to KRW 640.9 Bn in FY2025.
Cosmecca Korea Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Revenue396.5399.4470.7524.3640.9
Cost of revenue324.6335364.2400.2483.5
Gross profit71.964.4106.6124.1157.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.